Literature DB >> 25924987

Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study.

Kajsa Sjöholm1, Pia Pajunen, Peter Jacobson, Kristjan Karason, C David Sjöström, Jarl Torgerson, Lena M S Carlsson, Lars Sjöström, Markku Peltonen.   

Abstract

AIMS/HYPOTHESIS: The aim of this work was to analyse the rates of incidence and remission of type 2 diabetes in relation to baseline BMI and weight change in the prospective, controlled Swedish Obese Subjects (SOS) study.
METHODS: Three-thousand four-hundred and eighty-five obese individuals receiving bariatric surgery or conventional treatment were grouped into four baseline BMI categories (<35, 35-40, 40-45 or ≥ 45 kg/m(2)) and five weight-change categories according to their BMI at 2 years (increase [≥ 1 BMI unit increase], no change [less than 1 BMI unit change], minor reduction [-1 to -9 BMI units], medium reduction [-10 to -14 BMI units] and major reduction [< -15 BMI units]). The incidence and remission of diabetes at 2 years was assessed.
RESULTS: Among individuals with no weight change, diabetes incidence rates were 5.5%, 7.4%, 8.3% and 5.2%, in the four baseline BMI categories, respectively. In those with an initial BMI of 35-40, 40-45 and ≥ 45 kg/m(2) who attained a minor reduction in weight, the corresponding rates were 1.3%, 1.2% and 3.4%, respectively. In both the medium- and major-weight-reduction groups, diabetes incidence was ≤ 0.5%. Among individuals with diabetes at baseline, the remission rates were 15.3-26.9% in the no-weight-change groups, and 48.1-70% for individuals who attained a minor weight reduction. In the medium- and major-weight-reduction groups, the remission rate was 77-97%. There were no differences in 2 year incidence and remission rates between different baseline BMI groups that achieved the same degree of weight reduction. CONCLUSIONS/
INTERPRETATION: In obese individuals, the favourable effect of weight reduction on type 2 diabetes incidence and remission is independent of initial BMI. Trial registration ClinicalTrials.gov number NCT01479452.

Entities:  

Mesh:

Year:  2015        PMID: 25924987     DOI: 10.1007/s00125-015-3591-y

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  23 in total

Review 1.  Regression to the mean: what it is and how to deal with it.

Authors:  Adrian G Barnett; Jolieke C van der Pols; Annette J Dobson
Journal:  Int J Epidemiol       Date:  2004-08-27       Impact factor: 7.196

2.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.

Authors:  Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

3.  Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial.

Authors:  Robert E Steinert; Ralph Peterli; Sylvia Keller; Anne C Meyer-Gerspach; Jürgen Drewe; Thomas Peters; Christoph Beglinger
Journal:  Obesity (Silver Spring)       Date:  2013-08-13       Impact factor: 5.002

4.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

Authors:  S J Pocock; R Simon
Journal:  Biometrics       Date:  1975-03       Impact factor: 2.571

Review 5.  Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action.

Authors:  Francesco Rubino; Philip R Schauer; Lee M Kaplan; David E Cummings
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

6.  Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects.

Authors:  Lena M S Carlsson; Markku Peltonen; Sofie Ahlin; Åsa Anveden; Claude Bouchard; Björn Carlsson; Peter Jacobson; Hans Lönroth; Cristina Maglio; Ingmar Näslund; Carlo Pirazzi; Stefano Romeo; Kajsa Sjöholm; Elisabeth Sjöström; Hans Wedel; Per-Arne Svensson; Lars Sjöström
Journal:  N Engl J Med       Date:  2012-08-23       Impact factor: 91.245

7.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

Authors:  Jarl S Torgerson; Jonathan Hauptman; Mark N Boldrin; Lars Sjöström
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

8.  Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial.

Authors:  Lars Sjöström; Anders Gummesson; C David Sjöström; Kristina Narbro; Markku Peltonen; Hans Wedel; Calle Bengtsson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Peter Jacobson; Kristjan Karason; Jan Karlsson; Bo Larsson; Anna-Karin Lindroos; Hans Lönroth; Ingmar Näslund; Torsten Olbers; Kaj Stenlöf; Jarl Torgerson; Lena M S Carlsson
Journal:  Lancet Oncol       Date:  2009-06-24       Impact factor: 41.316

9.  Effects of bariatric surgery on mortality in Swedish obese subjects.

Authors:  Lars Sjöström; Kristina Narbro; C David Sjöström; Kristjan Karason; Bo Larsson; Hans Wedel; Ted Lystig; Marianne Sullivan; Claude Bouchard; Björn Carlsson; Calle Bengtsson; Sven Dahlgren; Anders Gummesson; Peter Jacobson; Jan Karlsson; Anna-Karin Lindroos; Hans Lönroth; Ingmar Näslund; Torsten Olbers; Kaj Stenlöf; Jarl Torgerson; Göran Agren; Lena M S Carlsson
Journal:  N Engl J Med       Date:  2007-08-23       Impact factor: 91.245

Review 10.  Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Viktoria L Gloy; Matthias Briel; Deepak L Bhatt; Sangeeta R Kashyap; Philip R Schauer; Geltrude Mingrone; Heiner C Bucher; Alain J Nordmann
Journal:  BMJ       Date:  2013-10-22
View more
  25 in total

Review 1.  [Obesity and type 2 diabetes].

Authors:  Hermann Toplak; Friedrich Hoppichler; Thomas C Wascher; Karin Schindler; Bernhard Ludvik
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

2.  Diabetes remission off medications is not a suitable endpoint for comparing bariatric/metabolic surgery with pharmacotherapy.

Authors:  Bruno Halpern; Cintia Cercato; Marcio C Mancini
Journal:  Diabetologia       Date:  2016-06-16       Impact factor: 10.122

3.  The Mitigating Effect of Phentermine and Topiramate on Weight Regain After Roux-en-Y Gastric Bypass Surgery.

Authors:  Nawfal W Istfan; Wendy A Anderson; Donald T Hess; Liqun Yu; Brian Carmine; Caroline M Apovian
Journal:  Obesity (Silver Spring)       Date:  2020-06       Impact factor: 5.002

Review 4.  A review of the psychosocial aspects of clinically severe obesity and bariatric surgery.

Authors:  David B Sarwer; Leslie J Heinberg
Journal:  Am Psychol       Date:  2020 Feb-Mar

5.  Conversion from Prediabetes to Diabetes in Individuals with Obesity, 5-Years Post-Band, Sleeve, and Gastric Bypass Surgeries.

Authors:  Dror Dicker; Doron S Comaneshter; Rina Yahalom; Chagit Adler Cohen; Shlomo Vinker; Rachel Golan
Journal:  Obes Surg       Date:  2019-12       Impact factor: 4.129

6.  The Impact of Preoperative BMI (Obesity Class I, II, and III) on the 12-Month Evolution of Patients Undergoing Laparoscopic Gastric Bypass.

Authors:  Eva M Ramírez; Omar Espinosa; Ricardo Berrones; Elisa M Sepúlveda; Lizbeth Guilbert; Miguel Solís; Carlos Zerrweck
Journal:  Obes Surg       Date:  2018-10       Impact factor: 4.129

7.  Bariatric/Metabolic Surgery to Treat Type 2 Diabetes in Patients With a BMI <35 kg/m2.

Authors:  David E Cummings; Ricardo V Cohen
Journal:  Diabetes Care       Date:  2016-06       Impact factor: 19.112

8.  Approach to the Patient: Management of the Post-Bariatric Surgery Patient With Weight Regain.

Authors:  Nawfal W Istfan; Marine Lipartia; Wendy A Anderson; Donald T Hess; Caroline M Apovian
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

9.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations.

Authors:  Francesco Rubino; David M Nathan; Robert H Eckel; Philip R Schauer; K George M M Alberti; Paul Z Zimmet; Stefano Del Prato; Linong Ji; Shaukat M Sadikot; William H Herman; Stephanie A Amiel; Lee M Kaplan; Gaspar Taroncher-Oldenburg; David E Cummings
Journal:  Obes Surg       Date:  2017-01       Impact factor: 4.129

Review 10.  Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way.

Authors:  Deborah R Leitner; Gema Frühbeck; Volkan Yumuk; Karin Schindler; Dragan Micic; Euan Woodward; Hermann Toplak
Journal:  Obes Facts       Date:  2017-10-12       Impact factor: 3.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.